Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00894413 · ClinicalTrials.gov registry record · Phase 2
A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00894413 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 45 participants.
The verdict
NCT00894413, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine whether or not Cialis (tadalafil) administered to head and neck squamous cell cancer patients augments immune response.
Interventions
- DRUG Tadalafil
- OTHER Placebo Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2007-05-08 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00894413
The ClinicalTrials.gov registry entry for NCT00894413 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tadalafil is the first listed.
NCT00894413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00894413 about?
NCT00894413 is a clinical study titled "A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract". The purpose of this trial is to determine whether or not Cialis (tadalafil) administered to head and neck squamous cell cancer patients augments immune response.
What is the current status of trial NCT00894413?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2007-05-08. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00894413?
The interventions under investigation include: Tadalafil (DRUG), Placebo Pill (OTHER).
Who is sponsoring clinical trial NCT00894413?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.